BioXcel Therapeutics Faces Delisting Notice

TL;DR

BioXcel got a notice about possibly getting delisted. Big trouble.

AI Summary

BioXcel Therapeutics, Inc. filed an 8-K on September 20, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, incorporated in Delaware with its principal executive offices in New Haven, CT, is subject to this filing as of September 16, 2024.

Why It Matters

This filing indicates potential issues with BioXcel Therapeutics' continued listing on a stock exchange, which could significantly impact its stock price and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock viability and investor confidence.

Key Players & Entities

• BioXcel Therapeutics, Inc. (company) — Registrant
• September 16, 2024 (date) — Earliest event reported
• September 20, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• New Haven, CT (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 B — h registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
• $0.001 — r the Company's common stock, par value $0.001 per share, had closed below the $1.00 p
• $1.00 — $0.001 per share, had closed below the $1.00 per share minimum bid price requirement
• $35 million — ted securities was below the minimum of $35 million required for continued listing on the N
• $35.0 million — pany's common stock must meet or exceed $35.0 million for a minimum of 10 consecutive busines

Filing Documents

• tm2424352d1_8k.htm (8-K) — 33KB
• 0001104659-24-101689.txt ( ) — 204KB
• btai-20240916.xsd (EX-101.SCH) — 3KB
• btai-20240916_lab.xml (EX-101.LAB) — 33KB
• btai-20240916_pre.xml (EX-101.PRE) — 22KB
• tm2424352d1_8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K ("Form 8-K") includes "forward-looking 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Form 8-K other than Company's intent to monitor the bid price of its common stock and consider available options to regain compliance with the minimum bid price requirement and the minimum market value of listed securities requirement; the Company's eligibility for an additional 180 calendar day compliance period to comply with the minimum bid price requirement; and the expected timing of any of the foregoing. When used herein, words including "anticipate," "believe," "can," "continue," "could," "designed," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actua

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOXCEL THERAPEUTICS, INC. Date: September 20, 2024 By: /s/ Richard Steinhart Name: Richard Steinhart Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR